Clinical Trial Update: A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) [Phase 2]

View source ↗

Summary

Phase 2 trial update for ICP-022 in relapsed/refractory marginal zone lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• ICP-022

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: MZL | Phase 2 | Status: COMPLETED